Statement from Quincy Bioscience on Federal Jury Verdict

Madison, Wis. (March 11, 2024) - Today, a jury in the United States District Court for the Southern District of New York issued a verdict in Federal Trade Commission et al. v. Quincy Bioscience Holding Company, Inc. et al. Quincy Bioscience shared the following statement:

“We are pleased that a federal jury in New York concluded today that the New York Attorney General failed to prove its deceptive advertising and labeling case against Quincy Bioscience's key advertising claims for Prevagen®, including the claim that Prevagen ‘improves memory.’

At great expense to taxpayers, the New York Attorney General’s office, aided by the Federal Trade Commission, has pursued this case for more than seven years. With the jury trial now concluded, we plan to refocus our time and resources on continuing to lead the way in brain health with our cutting-edge applications of Prevagen.”

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin, focused on the discovery, development and
commercialization of novel technologies to support brain health, with a specific emphasis on memory support and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the patented protein apoaequorin, which has been tested to show improvements in cognition and memory in clinical trials.